Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Vivo TCA Cycle Flux Assessment
NCT02748369Phase 1Completed
- Start
- Jul 2016
- Primary completion
- Mar 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of somatostatin and glucagon (2 arms). Primary endpoint: In Vivo TCA cycle flux in skeletal muscle and splanchnic tissue at 12 hours. Started Jul 2016; status: completed.
02
Drugs
somatostatinglucagon
Beyond the preview
Go deeper on NCT02748369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748369.